Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Dusit Medical Services PCLBDUUF 93 3-Year EBITDA Growth Rate is 5.80% as of Jun. 2026, which is 51% below its 10-year median of 11.85. GuruFocus rates BDUUF with a GF Score™ of 93/100 and a GF Value™ of $0.79. The stock has 2 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Bangkok Dusit Medical Services PCL ranks worse than 58.89% on this metric.
During the past 12 months, Bangkok Dusit Medical Services PCL's average EBITDA Per Share Growth Rate was -2.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bangkok Dusit Medical Services PCL was 46.50% per year. The lowest was -4.90% per year. And the median was 11.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bangkok Dusit Medical Services PCL 3-Year EBITDA Growth Rate Related Terms
BDUUF vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Bangkok Dusit Medical Services PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Dusit Medical Services PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bangkok Dusit Medical Services PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bangkok Dusit Medical Services PCL's 3-Year EBITDA Growth Rate falls into.
Bangkok Dusit Medical Services PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.80% mean?
Bangkok Dusit Medical Services PCL (BDUUF) has a 3-Year EBITDA Growth Rate of 5.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bangkok Dusit Medical Services PCL and its competitors. This is 51% below median its historical median of 11.85. According to the industry distribution chart, Bangkok Dusit Medical Services PCL ranks #308 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 58.9%.
Is Bangkok Dusit Medical Services PCL's 3-Year EBITDA Growth Rate too high?
Bangkok Dusit Medical Services PCL's current 3-Year EBITDA Growth Rate of 5.80% is 51% below median its 10-year median of 11.85. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Bangkok Dusit Medical Services PCL's value of 5.80% is 41.4% below this industry median. Based on the distribution chart, Bangkok Dusit Medical Services PCL ranks #308 out of 523 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Bangkok Dusit Medical Services PCL has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Dusit Medical Services PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Bangkok Dusit Medical Services PCL ranks #308 out of 523 companies for 3-Year EBITDA Growth Rate. This places Bangkok Dusit Medical Services PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Bangkok Dusit Medical Services PCL's value of 5.80% is 41.4% below this benchmark. While the company's 10-year median is 11.85 vs. the industry median of 9.90, Bangkok Dusit Medical Services PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Dusit Medical Services PCL's current 3-Year EBITDA Growth Rate of 5.80% is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bangkok Dusit Medical Services PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Dusit Medical Services PCL's current 3-Year EBITDA Growth Rate is 5.80%, which is 51% below median its own 10-year median of 11.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Dusit Medical Services PCL stock overvalued right now?
Bangkok Dusit Medical Services PCL (BDUUF) has a current 3-Year EBITDA Growth Rate of 5.80%. The stock's GF Value™ is $0.79, compared to a current price of $0.64 — trading 18.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.80%, which is 51% below median its 10-year median of 11.85 and 41.4% below the Healthcare Providers & Services industry median of 9.90. Bangkok Dusit Medical Services PCL's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bangkok Dusit Medical Services PCL (BDUUF), the current 3-Year EBITDA Growth Rate is 5.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bangkok Dusit Medical Services PCL (BDUUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bangkok Dusit Medical Services PCL stock appears to be undervalued.
The current stock price of $0.64 is trading 18.6% below its estimated GF Value™ of $0.79.
Key valuation signals for BDUUF:
3-Year EBITDA Growth Rate: 5.80% (51% below median its 10-year median of 11.85)
GF Value™: $0.79 vs. price of $0.64 (18.6% below fair value)
Industry Position: 41.4% below the Healthcare Providers & Services median (#308 of 523)
No single metric tells the full story. See the BDUUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bangkok Dusit Medical Services PCL operates a network of private hospitals in Thailand and some overseas markets, under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. The company has two business segments, namely hospital operations and other businesses that support hospital business, such as medical laboratories, production and distribution of pharmaceutical products/medical equipment/saline, pharmacies, asset management for healthcare business, accounting services, technology and information services, training business, and insurance broker. The company's hospital operations generate the vast majority of its revenue.
93GF Score
Get the complete analysis for BDUUF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDUUF has been successfully added to your 
